期刊
PEDIATRIC BLOOD & CANCER
卷 63, 期 6, 页码 973-982出版社
WILEY
DOI: 10.1002/pbc.25939
关键词
acute lymphoblastic leukemia; acute myeloid leukemia; hematopoietic stem cell transplantation; leukemia; leukemic relapse; minimal residual disease; pediatric; prognostication; risk stratification
资金
- Ontario Ministry of Health and Long-Term Care (MOHLTC)
Minimal residual disease (MRD) is an independent predictor of relapse risk in children with leukemia and is widely used for risk-adapted treatment. This article summarizes current evidence supporting the use of MRD, including clinical significance, current international clinical practice, impact statement, and recommended indications. The proposed MRD recommendations have been endorsed by the MRD Working Group of the Pediatric Oncology Group of Ontario and provide the foundation for a strategy that aims at equitable access to MRD evaluation for children with leukemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据